Veracyte, Inc. director Jens Holstein filed a Form 4 with the SEC on October 28, 2026, reporting two sets of stock option exercises and corresponding share sales in Common Stock executed on September 24, 2026 and October 27, 2026 under a Rule 10b5-1 plan.

Key Highlights

  • Reporting person: Jens Holstein, identified as a Director of Veracyte, Inc. (NASDAQ:VCYT).
  • September 24 transactions: Holstein exercised a stock option for 7,500 shares at $35.3 per share (transaction code M) and sold 7,500 shares of Common Stock at $47 per share (transaction code S).
  • October 27 transactions: Holstein exercised a stock option for 7,500 shares at $35.3 per share and sold 7,500 shares at $50 per share.
  • Beneficial ownership after October 27: 27,471 shares of Common Stock held directly, with 20,000 stock options remaining, according to the filing.
  • Rule 10b5-1 plan: Both sets of transactions were made pursuant to a plan adopted by Holstein on June 12, 2026.
  • Late report noted: The September 24 transactions were "not timely reported due to an inadvertent administrative error not attributable to the reporting person," as stated in the filing.

Holstein's Option Exercises and Share Sales at Veracyte

According to the Form 4 filed October 28, 2026, Jens Holstein, a director of Veracyte, Inc. (NASDAQ:VCYT), reported four transactions across two dates. On September 24, 2026, Holstein exercised a fully vested stock option to acquire 7,500 shares of Common Stock at $35.3 per share, then sold 7,500 shares at $47 per share. Following those transactions, his directly held Common Stock position stood at 27,471 shares, with 27,500 stock options remaining at that point.

On October 27, 2026, Holstein again exercised a fully vested stock option for 7,500 shares at $35.3 per share and sold 7,500 shares at $50 per share. After these transactions, his directly held Common Stock position remained at 27,471 shares, and his remaining stock options declined to 20,000, per the filing. The stock options carry an exercise price of $35.3 and an expiration date of August 1, 2030.

The filing states all transactions were executed pursuant to a Rule 10b5-1 trading plan that Holstein adopted on June 12, 2026. The filing further notes that the September 24, 2026 transactions were not reported on a timely basis, attributing the delay to "an inadvertent administrative error not attributable to the reporting person." The Form 4 was signed by Jonathan Wygant as attorney-in-fact on October 28, 2026.

What Was Disclosed

Director Jens Holstein disclosed the exercise of stock options and sale of Veracyte Common Stock on two dates in September and October 2026, all under a pre-established 10b5-1 plan, with a late-filing note for the September transactions.